Overview

Randomized Trial of Radiation Therapy With and Without Rituximab for Patients With Stage I II Follicular Lymphoma Grade I/II

Status:
Recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if adding rituximab to radiation therapy will help control the disease better than radiation alone. The safety of this combination will also be studied. Radiation therapy is designed to kill cancer cells or to stop cancer cells from growing. Rituximab is designed to attach to cancer cells that have CD20 (a tumor marker) on their surface and damage them, which may cause the cells to die.

Phase:

N/A

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Rituximab